πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Sertraline

    The First People's Hospital of Lianyungang

    Efficacy, Team

    approved small molecule completed

    1 trial

  2. Sertraline Hydrochloride

    The First People's Hospital of Lianyungang

    COVID-19 Vaccine Adverse Reaction

    approved small molecule completed

    1 trial

  3. Shenfu Injection

    The First People's Hospital of Lianyungang

    Septic Shock

    approved small molecule active

    2 trials

  4. Skin stretching device (SSD)

    The First People's Hospital of Lianyungang

    Trauma

    approved other active

    1 trial

  5. Standard BP control

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  6. Statin

    The First People's Hospital of Lianyungang

    Acute Coronary Syndrome

    approved small molecule active

    1 trial

  7. Sufentanil

    The First People's Hospital of Lianyungang

    Arteriovenous Malformation

    approved small molecule active

    1 trial

  8. Tamsulosin Oral Capsule

    The First People's Hospital of Lianyungang

    Ischaemic Heart Disease (IHD)

    approved small molecule completed

    1 trial

  9. Tenofovir Alafenamide 25 MG

    The First People's Hospital of Lianyungang

    Chronic Hepatitis C

    approved small molecule active

    1 trial

  10. Tenofovir Alafenamide Tablets

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    approved small molecule active

    1 trial

  11. Thalidomide

    The First People's Hospital of Lianyungang

    Gastric Cancer

    approved small molecule active

    1 trial

  12. Tirzepatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial

  13. Tislelizumab

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    approved small molecule active

    1 trial

  14. Tislelizumab + cisplatin + paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    approved small molecule active

    1 trial

  15. Tocilizumab

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

  16. Tranexamic Acid

    The First People's Hospital of Lianyungang

    Postpartum Hemorrhage， Cesarean Section

    approved small molecule active

    1 trial

  17. Trastuzumab Rezetecan

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  18. Triple antithrombotic therapy

    The First People's Hospital of Lianyungang

    Acute Coronary Syndrome (ACS)

    approved small molecule active

    1 trial

  19. VAB-7

    The First People's Hospital of Lianyungang

    Helicobacter Pylori

    approved small molecule active

    1 trial

  20. Vancomycin

    The First People's Hospital of Lianyungang

    Blood Stream Infections

    approved small molecule active

    1 trial

  21. Vifor

    The First People's Hospital of Lianyungang

    Malnutrition

    approved small molecule completed

    1 trial

  22. Vonoprazan

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    approved small molecule active

    2 trials

  23. Vonoprazan

    The First People's Hospital of Lianyungang

    Ulcers, Gastric

    approved small molecule active

    1 trial

  24. Vonoprazan and Amoxicillin for the first 7 days

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection

    approved small molecule active

    1 trial

  25. Xingnaojing injection

    The First People's Hospital of Lianyungang

    Ischemic Stroke, Acute

    approved small molecule active

    1 trial

  26. Yiqitongluo granule

    The First People's Hospital of Lianyungang

    Stroke

    approved small molecule completed

    1 trial

  27. a control group

    The First People's Hospital of Lianyungang

    Disorder of Stomach Function and Feeding Problems in Newborn

    approved small molecule completed

    1 trial

  28. aspirin 100mg/d therapy

    The First People's Hospital of Lianyungang

    Coronary Atherosclerosis

    approved small molecule active

    1 trial

  29. aspirin and clopidogrel

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial

  30. berberine hydrochloride

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial

  31. butylphthalide(NBP)

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    approved small molecule completed

    1 trial

  32. dapagliflozin

    The First People's Hospital of Lianyungang

    Diabetic Kidney Disease

    approved small molecule active

    1 trial

  33. dexmedetomidine

    The First People's Hospital of Lianyungang

    Aged

    approved small molecule completed

    3 trials

  34. dexmedetomidine

    The First People's Hospital of Lianyungang

    Postoperative Cognitive Dysfunction

    approved small molecule active

    1 trial

  35. dexmedetomidine hydrochloride for injection

    The First People's Hospital of Lianyungang

    Delirium

    approved small molecule completed

    1 trial

  36. entecavir

    The First People's Hospital of Lianyungang

    Liver Fibrosis

    approved small molecule completed

    1 trial

  37. ginkgolide

    The First People's Hospital of Lianyungang

    Intravenous Alteplase Thrombolysis

    approved small molecule completed

    1 trial

  38. half-dose ticagrelor

    The First People's Hospital of Lianyungang

    Acute Coronary Syndrome

    approved small molecule active

    1 trial

  39. hydrochloride hydromorphone + flurbiprofen axetil

    The First People's Hospital of Lianyungang

    Enhanced Recovery After Surgery

    approved small molecule completed

    1 trial

  40. insulin lispro injection, exenatide injection

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  41. intravenous tranexamic acid (TXA) infusion

    The First People's Hospital of Lianyungang

    Spontaneous Intracranial Hemorrhage

    approved small molecule active

    1 trial

  42. iodixanol

    The First People's Hospital of Lianyungang

    Kidney Failure, Chronic

    approved small molecule active

    1 trial

  43. lorlatinib

    The First People's Hospital of Lianyungang

    NSCLC

    approved small molecule active

    1 trial

  44. low-dose ticagrelor

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    approved small molecule active

    1 trial

  45. low-dose ticagrelor

    The First People's Hospital of Lianyungang

    Platelet Reactivity

    approved small molecule completed

    1 trial

  46. minimally invasive cholecystolithotomy with gallbladder reservation

    The First People's Hospital of Lianyungang

    Gallstones

    approved other active

    1 trial

  47. mouse nerve growth factor

    The First People's Hospital of Lianyungang

    Cerebral Small Vessel Diseases

    approved small molecule active

    1 trial

  48. neoadjuvant therapy

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma Resectable

    approved other active

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.